ABSTRACT. The presence of epidermal growth factor (EGF) and transforming growth factor-a (TGFa) immunoreactivities in fetal human tissues was studied immunohistochemically at different gestational ages. EGF and TGFa immunoreactivities were detected from the 20th gestational wk. EGF immunoreactivity was limited to the small intestine, but TGFa immunoreactive cells were present in the colon also. According to radioreceptor assay, the intestine of a 19-wk-old human fetus contained 10 times more EGF receptor-binding substance than EGF, as measured by immunofluorometric assay. Chromatographic analysis suggests that TGFa-like peptides account for at least part of this activity, as so argues in favor of the presence of TGFa-and EGF-like peptides in the human fetal gut. Whether they are synthesized in the fetus is yet unknown. (Pediatr Res 26:25-30,1989) Abbreviations EGF, epidermal growth factor IFMA, time-resolved immunofluorometric assay PAP, peroxidase anti-peroxidase RP-HPLC, reverse-phase HPLC RRA, radioreceptor assay TGFa, transforming growth factor-a EGF and TGFa are structurally related mitogenic polypeptides (1, 2). They share the same receptor, EGF-R. EGF is a potent stimulator of cell multiplication and a modulator of the differentiation and function of cells of various types (1, 3, 4) . It inhibits gastric acid secretion and protects the gastric mucosa from damage by the acid (5-7). irhEGF has been detected by immunoassay methods in colostrum and milk, in several other body fluids and in tissue extracts (8, 9) . In adults it has been localized immunohistochemically to the submandibular salivary gland, the serous glands of the nasal cavity, the stomach, the Brunner's glands of the duodenum, the Paneth cells of the small intestine, the tubular cells of the kidney, the anterior pituitary, the bone marrow, and the sweat glands (10-13). In a 20-wk-old human fetus it was present in the kidney and the duodenal Paneth cells (1 2, 13). However, EGF appears in the amniotic fluid only from the 32nd gestational wk (X. Mattila, personal communication). Even at term its concentration is low, only about 0.3-0.96 ng/ml (14, 15), which suggests that it is not synthesized in large quantities during fetal life.
cell cultures (16) . It induces malignant transformation and anchorage-independent growth. TGFa has been found in fetal mouse tissues (17) . TGFa-mRNA has been demonstrated in various human tumors (18) , normal human neonatal and adult keratinocytes (19) , and rat decidua (20) . No TGFa-mRNA is detected in the normal human adult stomach or jejunum (18) .
TGFa has been proposed to be the fetal EGF (21) . In this study we tested this hypothesis mainly with immunohistochemical methods, using antisera to hEGF and hTGFa to examine human fetuses of different ages.
MATERIALS AND METHODS
Rat tissues. Male Sprague-Dawley rats weighing approximately 400 g were anesthetized with sodium pentobarbital and perfused with physiologic saline followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. The submandibular glands were removed, immersed in 4% paraformaldehyde for 2 h and then transferred to 20% sucrose-0.1 M sodium phosphate buffer for at least 24 h. Cryostat sections were cut at 20 pm for immunohistochemistry.
Human tissues. Fetal tissues (from a total of eight fetuses) were collected at legal abortions: at 14.5 wk the jejunum, liver, adrenals, kidney, lung, and gonads from one fetus, at 19 wk the duodenum, jejunum, ileum, lung, and parotid and submandibular glands from three fetuses, at 20 wk the jejunum, ileum, colon, liver, spleen, adrenals, lung, skin, and urinary bladder from two fetuses, and at 22 wk the stomach, duodenum, jejunum, kidney, parotid glands, liver, adrenals, hypophysis, and brain from two fetuses.
The duodenum was defined as the 10-cm portion distal and adjacent to the stomach, the jejunum as the next 20-cm portion, the ileum as the portion proximal to the ileocecal valve, and the colon as that distal to the ileocecal valve. The tissues were fixed in 4% paraformaldehyde, and those from the 19-, 20-and 22-wk-old fetuses also in acetone-ethanol (30:70), and embedded in paraffin. Biopsy specimens of normal adult duodenum were obtained at routine diagnostic gastroscopy and fixed in 4% paraformaldehyde like the rat tissues.
Primary antisera and peptides. Mouse monoclonal (ascites fluid, code numbers 2 and 4) and rabbit polyclonal (bleed number 2) anti-hEGF antibodies and pure biosynthetic hEGF were gifts from AMGen (Thousand Oaks, CA). rhTGFa and monoclonal hTGFa antibody were from Genentech (South San Francisco, CA).
Dot blot assay. EGF and TGFa were spotted as 2-p1 droplets (0.02 to 2 pmol) onto nitrocellulose membrane filters (pore size 0.45 pm, BA 35, Schleicher & Schuell Inc., Keene, NH), and fixed by exposure to paraformaldehyde vapor (30 min at 80°C). For comparison, similar unfixed filters were incubated. Antigen and antisera dilutions (1:1000 or 1:3000) were made in 0.1% BSA-PBS, pH 7.4. The filters were incubated at room tempera-ture in a shaker. Nonspecific binding was blocked with 2% BSA-0.1 M PBS, pH 7.4, for 2 h. Incubation with the primary antiserum, preimmune serum, or preabsorbed antiserum (with 0.1-1.0 pM hEGF or hTGFa overnight at +4"C) was for 1 h in 300 p1 Eppendorf tubes pressed upward onto the antigen spots. The filters were washed twice for 10 min in 0. l M PBS, pH 7.4, before addition of the second antiserum (swine antirabbit Ig 1 : 100, rabbit anti-mouse Ig 1 :80, DAKO, Copenhagen, Denmark). Incubation with the peroxidase anti-peroxidase reagent (rabbit-PAP 1 : 150, mouse-PAP 1 :400, DAKO, Copenhagen, Denmark) was carried out for 45 min. The filters were rinsed in 0.05 M Tris-HCL, pH 7.6, for 2 x 10 min. The antigen-antiserum reaction was visualized with 3'3-diaminobenzidine tetrahydrochloride 50 mg/100 ml (Sigma Chemical Co., St. Louis, MO) and 0.05% hydrogen peroxide in 0.05 M Tris-HC1, pH 7.6. The Tris-HC1 wash was again repeated and the filters were dried for inspection, densitometric scanning, and photography.
Zmmunohistochemistry. The acetone fixed tissues were embedded in paraffin and 10-pm sections were cut on coated slides. The parafin sections were rehydrated in a graded series of alcohols. Tissues fixed in paraformaldehyde were frozen and 20-pm cryostat sections were cut. The immunoreactions were visualized with the FITC technique (22); 0.1 M PBS-0.25% Triton, pH 7.4, was used in all dilutions and washes. Nonspecific binding was blocked with normal swine or rabbit serum (dilutions 1:5, DAKO, Copenhagen, Denmark). Incubations with the primary antiserum, preimmune serum or preabsorbed antiserum (with 1 -10 pM hEGF or hTGFa overnight at +4"C) were carried out for 24 h at +4"C. Generally, antisera were diluted 1:1000. After two PBS-T washes the slides were incubated with the second antiserum (FITC-conjugated rabbit anti-mouse and swine antirabbit Ig 1:40, DAKO, Copenhagen, Denmark) for I h at room temperature. The slides were then washed in PBS and coated with PBS-glycerol (I: I) for examination by fluorescence micros-COPY.
Tissue extraction. About 10 cm of small intestine from a 19-wk-old human fetus was homogenized in 1 M acetic acid and centrifuged at 35000 rpm for 30 min. The supernatant was collected and divided into 1-ml aliquots, which were lyophilized and dissolved in appropriate buffers for protein determination (23), EGF-IFMA (24), EGF-RIA (25), RRA, and RP-HPLC. EGF-IFMA or EGF-RIA did not cross-react with TGFa.
Radioreceptor assay. Samples, receptor preparation (mouse liver homogenate) and 1251-hEGF (1 5000 cpm) in Tris-HC1 10 mM-NACI 50 mM-0.25% BSA buffer, pH 7.4, were incubated at room temperature for 90 min. The unbound and receptorbound label were separated by centrifugation at 3200 rpm for 25 min at +4"C. he-radioactivity of the pellet was measured.
Unlabeled hEGF was used as a ligand for the standard curve.
RP-HPLC. The lyophilized extract was dissolved in 0.1 M acetic acid and ultrafiltered through a membrane with a 10-KDa cut-off (Ultrafree Pf, PLGC membrane, Millipore Continental Water Systems, Bedford, MA). The filtrate was collected, lyophilized, and dissolved in eluent A. Through a Rheodyne injector valve, 50 p1 were injected onto an LKB-Ultropac TSK-ODs 120 T column (4.6 mm x 250 mm, 0.5 pm particle size). The column was eluted with a gradient from eluent A (10% acetonitrile-90% water) to eluent B (65% acetonitrile-35% water). Both eluents contained 0.5% trifluoroacetate and morpholine as additives. The flow rate was 0.8 ml/min. The gradient was started after a 4-min plateau of 90% eluent A. From 5-10 min the percentage of B was raised linearly to 30% and from 11-55 min linearly to 60%. The 0.8 ml fractions were collected. For protein protection, 100 p1 0.1 % BSA were added to the aliquots. All fractions were lyophilized and analyzed for both irhEGF and irhTGFa with the dot blot assay using hEGF and hTGFa antibodies, and with EGF-IFMA and RRA. hEGF and hTGFa standards were run similarly. Before running the tissue sample a blank run was made to check for possible cany-over from standard runs.
RESULTS

Specificity of antisera.
To verify the affinity of hEGF antibodies to hEGF, we performed model experiments on nitrocellulose filters (Fig. I ). Every hEGF antibody tested recognized hEGF, and preabsorption with 0.1-1 pM hEGF abolished the reaction. The antibodies did not cross-react with hTGFa (data not shown).
In the dot blot experiments anti-hTGFa cross-reacted with hEGF ( Fig. 2) . Preabsorption with 0.1 pM hTGFa abolished the hEGF reactivity but retained the hTGFa reaction. A 10-fold concentration of hTGFa (1 pM) abolished the hTGFa reactivity. Preabsorption with 1.0 pM hEGF had little or no effect (densitometrically scanned intensities of the dots were almost equal), suggesting that the antibody had a much higher affinity for hTGFa than for hEGF or that the unwanted cross-reaction was due to nonimmunologic factors.
Hence we conclude that the hTGFa immunoreaction is specific in those cellular sites in which it was abolished by preabsorption with hTGFa but not with excess hEGF. E G F immunohistochemistry. The positive tissue controls were human adult duodenum, in which the fluorescence was seen in the Paneth cells and Brunner's glands (Fig. 30) and human and rat submandibular glands. Preabsorption of the antiserum with 0.00 1 -1 . O pM hEGF diminished the intensity of the fluorescence, but did not abolish it completely (Fig. 3b) . Similar sections stained with the preimmune serum were generally negative, but occasional fluorescent cells were seen. The polyclonal anti-hEGF detected hEGF immunoreactive cells in 19- (Fig. 4) and 20-wk-old (Fig. 5 ) human fetal jejunal crypts of Lieberkiihn and Brunner's glands. Fluorescence was also seen in the ileum of a 19-wk-old fetus. To our surprise the monoclonal anti-hEGF recognized much more irhEGF in the jejunum and in the 20-wk-old ileum (Figs. 4-6 Table 1 .
TGFa immunohistochemistry. The anti-hTGFa caused strong staining of the villi and crypts of Lieberkiihn in paraformaldehyde-fixed 19-wk-old human fetal duodenum, jejunum and ileum (Figs. 4 and 7 ) and in the 20-wk-old fetus it also stained the epithelial and cryptal cells of the colon (Figs. 5 , 6 , and 8).
The fluorescence pattern was linear or formed a granular ring to the peripheral cytoplasm. Replacing the antibody with normal mouse serum gave no staining. Preabsorption of anti-hTGFa with 1 pM hTGFa diminished and with 10 pM hTGFa nearly abolished the fluorescence. One FM hEGF had generally no effect on it, although in some consecutive sections the fluorescence was slightly diminished. The results were similar in acetone-fixed tissues and with the peroxidase anti-peroxidase technique. We consider that the fluorescence pattern obtained with antiTGFa represents irTGFa. This is supported by the data from HPLC experiment.
The hTGFa fluorescence was much weaker in a 22-wk-old fetal jejunum. Also, in 22-wk-old fetuses irTGFa was observed b). Both monoclonal hEGF antisera stain rather weakly; the figure shows " pAE, polyclonal anti-hEGF; mAE, monoclonal anti-hEGF; preimmune, preimmune serum; NMS, normal mouse serum; E, hEGF; +++, very strong fluorescence; ++, strong; +, moderate; (+), weak; 0, no staining; -, not examined; AC, acetone fixation; PFA, paraformaldehyde fixation; c, colon; d, duodenum; j, jejunum; k, kidney; p, parotid gland; s, submandibular gland.
irEGF AND irTGFa IN FETAL GUT 29 only in a few cells and in the villous epithelium instead of a strong cryptal reaction. All other tissues examined were negative for hTGFa. The results are summarized in Table 2 
RP-HPLC results.
A single hTGFa-immunoreactive peak corresponding to the elution time of authentic hTGFa was detected in RP-HPLC analysis of the intestinal extract. No immunoreactivity was found in the irTGFa-peak or in any other fraction with the hEGF antibody (Fig. 9 ). In accordance with this RRA detected some receptor binding substance in the irTGFa-peak while EGF-IFMA could not detect any EGF.
DISCUSSION
The results suggest that hTGFa-immunoreactive peptide, which in RP-HPLC shows characteristics of hTGFa and has an affinity for the EGF receptor, is present in developing human intestine. Moreover, an EGF-like peptide was also found in the same tissue.
Although our monoclonal anti-hTGFa reacted in the nitrocellulosa model also with hEGF, the reactivity to hTGFa was much greater. In the RP-HPLC analysis of fragments of 19-and tissue extract EGF-IFMA did not detect any hEGF. In a 19-wkold human fetal intestine RRA measured 20 times more receptor binding substance than could be accounted for EGF as measured by EGF-IFMA.
To conclude, despite the anti-hTGFa cross-reactivity with EGF, results of RP-HPLC, RRA, IFMA, and RIA, preabsorption controls, and the weaker fluorescence with the mono-and polyclonal anti-hEGF than with the anti-hTGFa, all suggest the presence of both TGFa-and EGF-like peptides in the fetal gut.
A large number of irhEGF-and irTGFa-containing cells were detected throughout the intestine of 19-to 22-wk-old human fetuses. In the colon a positive fluorescence reaction was obtained only with the anti-hTGFa and in the jejunum the TGFa reaction was much stronger than the hEGF reaction.
Our immunohistochemical results show that the proximal intestine may contain more irEGF and irTGFa than the distal part. This could be associated with the faster rate of the cell cycle in the small intestine (26) . The strongest fluorescence is seen in all the segments in the proliferative zone, i.e., the crypts in the small intestine and the lower two-thirds of the colonic crypts. This also suggests a mitogenic role for EGF-and TGFa-like peptides in the intestinal epithelium.
In fetal mice Nexo et al. (27) measured a 10-fold higher EGF content by RRA than by RIA, suggesting that the fetal EGF differs from the adult form. Popliker et al. (28) did not find any EGF-mRNA from mouse fetuses, fetal membranes or placentae. The first detectable transcription was in the kidneys at 2 wk postpartum. TGFa-mRNA has been localized predominantly to rat maternal decidua, and not to the embryo itself (20) . Most of 20-wk-old small intestine, only a ~TGF~-immunoreactive frac- used. Then 0.8-ml fractions were collected. All fractions were analyzed Fig. 8 . In a 21-wk-old human fetus hTGFa antibody stains colonic for reactivities to both hEGF and hTGFa antibodies. The dots represent epithelial cells (urrow, a ) and the ductal crypts (b). All EGF antisera the intensity of the immunoreaction obtained in the dot blot assay. failed to stain any structures. Bar 25 pm.
Arrows mark hEGF and hTGFa standards. the luminal EGF in adults originates from the salivary glands and Brunner's glands; sialectomy significantly reduces the gastric content of EGF (29) . In our study the source of both irEGF and irTGFa in the intestine during fetal life remains unclear. They could be carried to the fetus by the blood from the placenta or the decidua. Or the fetal kidneys might synthesize and excrete them into the amniotic fluid and the intestinal villi may absorb the peptides from the amniotic fluid swallowed-although with the antibodies used, we could not detect any irEGF/TGFa in the kidney. And finally, the intestine might represent the site of synthesis, as it does in adults. In situ hybridization studies will show whether any synthesis does occur in the human fetus.
